Glioblastoma: Molecular analysis and clinical implications

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 59-70

  Huse, Jason T ^a   Holland, Eric ^a   DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

animal models; brain tumor; glioma; targeted therapy

Indexed keywords

CRIZOTINIB; DNA; ERLOTINIB; IMATINIB; PERIFOSINE; TEMOZOLOMIDE; VATALANIB; VEMURAFENIB;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC MYELOID LEUKEMIA; DISEASE CLASSIFICATION; DNA MICROARRAY; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; LUNG ADENOCARCINOMA; MELANOMA; MESENCHYME CELL; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GENETIC THERAPY; GENOMICS; GLIOBLASTOMA; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873029078     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-100711-143028     Document Type: Review

References (67)

1. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359:492-507
2. Dropcho EJ, Soong SJ. 1996. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology 47:684-90
3. Ohgaki H, Kleihues P. 2005. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64:479-89
4. Ohgaki H, Watanabe K, Peraud A, et al. 1999. A case history of glioma progression. Acta Neuropathol. 97:525-32
5. Scherer HJ. 1940. Cerebral astrocytomas and their derivatives. Am. J. Cancer 40:159-98
6. Huse JT, Phillips HS, Brennan CW. 2011. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 59:1190-99
7. The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-68
8. Parsons DW, Jones S, Zhang X, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-12
9. Alizadeh AA, Eisen MB, Davis RE, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-11
10. Perou CM, Sorlie T, Eisen MB, et al. 2000. Molecular portraits of human breast tumours. Nature 406:747-52
11. Fuller GN, Hess KR, Rhee CH, et al. 2002. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 12:108-16
12. Fuller GN, Rhee CH, Hess KR, et al. 1999. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 59:4228-32
13. Kim S, Dougherty ER, Shmulevich I, et al. 2002. Identification of combination gene sets for glioma classification. Mol. Cancer Ther. 1:1229-36
14. Rickman DS, Bobek MP, Misek DE, et al. 2001. Distinctive molecular profiles of high-grade and lowgrade gliomas based on oligonucleotide microarray analysis. Cancer Res. 61:6885-91
15. Sallinen SL, Sallinen PK, Haapasalo HK, et al. 2000. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60:6617-22
16. Shai R, Shi T, Kremen TJ, et al. 2003. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22:4918-23
17. Tanwar MK, GilbertMR, Holland EC. 2002. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62:4364-68
18. Karcher S, Steiner HH, Ahmadi R, et al. 2006. Different angiogenic phenotypes in primary and secondary glioblastomas. Int. J. Cancer 118:2182-89
19. Liang Y, Diehn M, Watson N, et al. 2005. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. USA 102:5814-19
20. Tso CL, Freije WA, Day A, et al. 2006. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 66:159-67
21. Verhaak RGW, Hoadley KA, Purdom E, et al. 2009. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
22. Noushmehr H, Weisenberger DJ, Diefes K, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-22
23. Phillips HS, Kharbanda S, Chen R, et al. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-73
24. Shen R, Mo Q, Schultz N, et al. 2012. Integrative subtype discovery in glioblastoma using iCluster. PLoS One 7:e35226
25. Brennan C, Momota H, Hambardzumyan D, et al. 2009. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4:e7752
26. Snuderl M, Fazlollahi L, Le LP, et al. 2011. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810-17
27. Szerlip NJ, Pedraza A, Chakravarty D, et al. 2012. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. USA 109:3041-46
28. Hambardzumyan D, Parada LF, Holland EC, et al. 2011. Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 59:1155-68
29. Ozawa T, Brennan CW, Wang L, et al. 2010. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 24:2205-18
30. Uhrbom L, Hesselager G, Nister M, et al. 1998. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 58:5275-79
31. AssanahM, Lochhead R, Ogden A, et al. 2006. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J. Neurosci. 26:6781-90
32. DaiC, Celestino JC, Okada Y, et al. 2001.PDGFautocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 15:1913-25
33. Shih AH, Dai C, Hu X, et al. 2004. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. 64:4783-89
34. Uhrbom L, Dai C, Celestino JC, et al. 2002. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res. 62:5551-58
35. Fomchenko EI, Dougherty JD, Helmy KY, et al. 2011. Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PLoS One 6:e20605
36. Lei L, Sonabend AM, Guarnieri P, et al. 2011. Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS One 6:e20041
37. Uhrbom L, Nerio E, Holland EC. 2004. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat. Med. 10:1257-60
38. Raymond E, Brandes AA, Dittrich C, et al. 2008. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol. 26:4659-65
39. Momota H, Nerio E, Holland EC. 2005. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 65:7429-35
40. Pitter KL, Galban CJ, Galban S, et al. 2011. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One 6:e14545
41. Katz AM, Amankulor NM, Pitter K, et al. 2012. Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS One 7:e32453
42. Charles N, Ozawa T, Squatrito M, et al. 2010. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6:141-52
43. Bleau AM, Hambardzumyan D, Ozawa T, et al. 2009. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4:226-35
44. Ding H, Shannon P, Lau N, et al. 2003. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res. 63:1106-13
45. Holland EC, Hively WP, DePinho RA, et al. 1998. A constitutively active epidermal growth factor receptor cooperates with disruption ofG1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 12:3675-85
46. WeissWA, Burns MJ, Hackett C, et al. 2003. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res. 63:1589-95
47. Zhu H, Acquaviva J, Ramachandran P, et al. 2009. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl. Acad. Sci. USA 106:2712-16
48. Zhu Y, Guignard F, Zhao D, et al. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8:119-30
49. Reilly KM, Loisel DA, Bronson RT, et al. 2000. Nf1; Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet. 26:109-13
50. Verhaak RG, Hoadley KA, Purdom E, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
51. Alcantara Llaguno S, Chen J, Kwon CH, et al. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15:45-56
52. Turcan S, Rohle D, Goenka A, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-83
53. Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-37
54. Talpaz M, Shah NP, Kantarjian H, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354:2531-41
55. Pao W, Miller V, Zakowski M, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101:13306-11
56. Lynch TJ, Bell DW, Sordella R, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-39
57. Kwak EL, Bang YJ, Camidge DR, et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363:1693-703
58. Chapman PB, Hauschild A, Robert C, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-16
59. Uhm JH, Ballman KV, Wu W, et al. 2011. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma:Mayo/North Central Cancer Treatment Group Study N0074. Int. J. Radiat. Oncol. Biol. Phys. 80:347-53
60. Reardon DA, Desjardins A, Vredenburgh JJ, et al. 2010. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 96:219-30
61. Prados MD, Chang SM, Butowski N, et al. 2009. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27:579-84
62. Brandes AA, Franceschi E, Tosoni A, et al. 2008. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26:2192-97
63. Reardon DA, Desjardins A, Vredenburgh JJ, et al. 2012. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer 118:4759-67
64. Reardon DA, Dresemann G, Taillibert S, et al. 2009. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br. J. Cancer 101:1995-2004
65. Copeland A, Buglio D, Younes A. 2010. Histone deacetylase inhibitors in lymphoma. Curr. Opin. Oncol. 22:431-36
66. Prins RM, Soto H, Konkankit V, et al. 2011. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 17:1603-15
67. Chi AS, Batchelor TT, Kwak EL, et al. 2012. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J. Clin. Oncol. 30:e30-33